17122-78-0 Usage
General Description
4-{[(2E)-2-(hydroxyimino)ethanoyl]amino}benzoic acid is a chemical compound with the molecular formula C11H10N2O4. It is a derivative of benzoic acid and contains a substituted amino group and a hydroxyimino group. 4-{[(2E)-2-(HYDROXYIMINO)ETHANOYL]AMINO}BENZOIC ACID has a wide range of potential applications in pharmaceuticals and medical research due to its unique structure and properties. It may be used as a building block in the synthesis of various pharmaceutical compounds and may also have potential biological activities. Further research is needed to fully understand the potential uses and properties of 4-{[(2E)-2-(hydroxyimino)ethanoyl]amino}benzoic acid.
Check Digit Verification of cas no
The CAS Registry Mumber 17122-78-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,7,1,2 and 2 respectively; the second part has 2 digits, 7 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 17122-78:
(7*1)+(6*7)+(5*1)+(4*2)+(3*2)+(2*7)+(1*8)=90
90 % 10 = 0
So 17122-78-0 is a valid CAS Registry Number.
InChI:InChI=1/C9H8N2O4/c12-8(5-10-15)11-7-3-1-6(2-4-7)9(13)14/h1-5,15H,(H,11,12)(H,13,14)/b10-5+
17122-78-0Relevant articles and documents
Synthesis, anti-lung cancer activity and molecular docking study of 3-methylene-2-oxoindoline-5-carboxamide derivatives
Ai, Juntao,Lv, Meng,Li, Xiaohui,Chen, Zhuo,Hu, Gaoyun,Li, Qianbin
, p. 161 - 170 (2018/04/17)
A series of 3-methylene-2-oxoindoline-5-carboxamide derivatives were synthesized in appreciable yield by using 4-aminobenzoic acid as a starting material. The preliminary biological test results showed that most compounds displayed potent inhibitory activity against proliferation of human lung adenocarcinoma epithelial cell line (A549) in MTT assay. Compound 6l displayed the highest potency (IC50 = 3.0 μM). The western blot analysis demonstrated a correlation between anti-proliferative activity of active compounds and blockade of the phosphorylation of extracellular signal-regulated kinases (ERK1/2). The docking study also provides new insights into further optimization of 3-methylene-2-oxoindoline-5-carboxamide derivatives for the discovery of more potent RAF/MEK/ERK pathway regulators as anti-lung cancer agents.
